Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,758 matching trials from the live ClinicalTrials.gov search.
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, gemcitabine hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
30
States / cities
Los Gatos, California • Tampa, Florida • Chicago, Illinois + 23 more
Conditions
Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer
Interventions
Momelotinib (MMB), Trametinib
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Duarte, California • Sacramento, California • Boston, Massachusetts + 2 more
Conditions
Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
Interventions
palifermin, cisplatin, placebo, neck dissection, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Scottsdale, Arizona • Auburn, California • Burbank, California + 40 more
Conditions
Bladder Cancer, Urethral Cancer, Urachal Cancer
Interventions
5-Fluorouracil (5-FU), Leucovorin, Cisplatin, Gemcitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Neuroendocrine Cancer, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Gastric Cancer
Interventions
thermochemotherapy, Cisplatin, Gemcitabine, Interferon-a
Other · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Nasopharyngeal Carcinoma
Interventions
Nivolumab, Cisplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
Sue Yom
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Conditions
Head and Neck Cancer, Squamous Cell Cancer
Interventions
zalutumumab, cisplatin, Radiotherapy
Drug · Procedure
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Lung Neoplasms
Interventions
ALIMTA, carboplatin, cisplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Springdale, Arkansas • Los Angeles, California • Fort Myers, Florida + 5 more
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, topotecan hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Neuroblastoma
Interventions
Protracted Oral Etoposide, Doxorubicin, IV Bolus Etoposide, Cisplatin, Cyclophosphamide, Mesna, Hematopoietic Factor, Primary tumor resection
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Endometrial Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
cisplatin, doxorubicin hydrochloride, low-LET photon therapy
Drug · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 46 more
Conditions
Urothelial Carcinoma Bladder, Androgen Receptor Positive
Interventions
Degarelix, Gemcitabine/Cisplatin
Drug · Combination Product
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Cisplatin, Radiotherapy
Drug · Radiation
Lead sponsor
Sara Medek
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Multiple Myeloma
Interventions
myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D
Device · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
73
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 54 more
Terminated Phase 2 Interventional Results available

Induction Chemo-Nivo in Unresectable Stage III NSCLC

NCT06003075
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage III
Interventions
Nivolumab and Chemotherapy, Nivolumab, Post Induction Surgery, Post Induction XRT
Combination Product · Drug · Procedure + 1 more
Lead sponsor
Ralph G Zinner
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Breast Cancer
Interventions
Filgrastim (G-CSF), Carmustine, Cisplatin, Cyclophosphamide (CTX), Etoposide, Thiotepa, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Houston, Texas
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lazertinib, Amivantamab, Pemetrexed, Carboplatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
28
States / cities
Mobile, Alabama • Tucson, Arizona • Duarte, California + 23 more
Conditions
Head and Neck Cancer
Interventions
cisplatin, gemcitabine hydrochloride
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
12
States / cities
Flemington, New Jersey • Mount Holly, New Jersey • Red Bank, New Jersey + 9 more
Conditions
Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8
Interventions
Cisplatin, External Beam Radiation Therapy, Nelfinavir
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
Interventions
Olaparib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
20
States / cities
Gilbert, Arizona • Orange, California • Stanford, California + 14 more
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
temsirolimus, cisplatin, cetuximab
Drug
Lead sponsor
University of Tennessee Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor, Malignant Ovarian Teratoma, Stage I Ovarian Choriocarcinoma, Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage I Testicular Choriocarcinoma AJCC v6 and v7, Stage I Testicular Embryonal Carcinoma AJCC v6 and v7, Stage I Testicular Seminoma AJCC v6 and v7, Stage I Testicular Yolk Sac Tumor AJCC v6 and v7, Stage II Ovarian Choriocarcinoma, Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage II Testicular Choriocarcinoma AJCC v6 and v7, Stage II Testicular Embryonal Carcinoma AJCC v6 and v7, Stage II Testicular Yolk Sac Tumor AJCC v6 and v7, Stage III Ovarian Choriocarcinoma, Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage III Testicular Choriocarcinoma AJCC v6 and v7, Stage III Testicular Embryonal Carcinoma AJCC v6 and v7, Stage III Testicular Yolk Sac Tumor AJCC v6 and v7, Stage IV Ovarian Choriocarcinoma, Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Teratoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
Interventions
Best Practice, Biopsy Procedure, Biospecimen Collection, Bleomycin Sulfate, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Pulmonary Function Test, Questionnaire Administration
Other · Procedure · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
1,780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
566
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 338 more
Conditions
Oropharyngeal Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Standard Radiation Treatment, Dose-Deescalated Treatment, Cisplatinum
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
New York, New York